Our Vision
We aim to empower patients for better healthcare with Artificial Intelligence.
AI in Healthcare is Our Passion
We develop advanced medical devices powered with Artificial Intelligence.
Solutions to Real Problems
We employ Artificial Intelligence for objective and clinically relevant analysis of medical images.
From Lund to New York
We are partnered with a global leader in theranostic medicine to target and treat cancer.


EXINI Agreement with
FUJIFILM Toyama Chemical Co. in Japan
As of June 18, 2019, EXINI, a wholly owned subsidiary of Progenics Pharmaceuticals Inc. has entered into a licence and transfer agreement with FUJIFILM Toyama Chemical Co, Ltd. (FFTC) for the rights to Automated Bone Scan Index (aBSI) product in Japan for use under the name BONENAVI.

aBSI has become an integral component of prostate cancer practice patterns in Japan, and we are delighted to continue our relationship with FFTC, a leading Japanese pharmaceutical and diagnostic company, to offer this optimized and quick response technology solution to support physician treatment decisions for prostate cancer patients.
Read More
highlighted at SNMMI 2019
June 24, at Anaheim, CA - EXINI team presented the performance of PSMA-AI device in an independent and prospectively defined study. The work was selected for an Oral presentation at SNMMI2019 and was picked for discussion in the highlight summary session. 

In a prospectively defined independent study, the data demonstrated that the AI-device assisted reads were better than manual only read in terms of speed, precision and diagnostic accuracy. The data is part of continual effort to enhance the clinical utility of imaging biomarkers with standardized and accurate assessment. 

Our focus remains on using technology to address clinically relevant questions for treatment management of Prostate Cancer. 
Read More


Read about our automatic bone scan index software.

Join Our Team

Find our open positions and send us your application.

Find Us at the Top of Lund

Get in contact with us.


Find out more about EXINI and what we do.